Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge


Page Path
HOME > J Yeungnam Med Sci > Volume 37(3); 2020 > Article
Case report
Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance
Dong Won Baek1,2orcid, Ji-Young Park2,3orcid, Soo Jung Lee1,2orcid, Yee Soo Chae1,2orcid
Yeungnam University Journal of Medicine 2020;37(3):230-235.
Published online: January 22, 2020

1Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea

2Kyungpook National University Cancer Research Institute, Daegu, Korea

3Department of Pathology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea

Corresponding author: Yee Soo Chae, Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, 807 Hoguk-ro, Buk-gu, Daegu 41404, Korea Tel: +82-53-200-2623 Fax: +82-53-200-2029 E-mail:
• Received: November 14, 2019   • Revised: December 9, 2019   • Accepted: December 23, 2019

Copyright © 2020 Yeungnam University College of Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 153 Download
  • 7 Crossref
  • Systemic therapy for metastatic triple-negative breast cancer (TNBC) still remains challenging because there are no targeted agents or endocrine therapies currently available. The present case report documents the successful use of cisplatin monotherapy to manage a heavily pretreated TNBC patient showing poor response to therapy. The patient was a 51-year-old woman who had already undergone several lines of systemic chemotherapy for widespread TNBC. Although the mutation analysis performed on DNA isolated from blood cells and progressed lesion samples confirmed the tumor to be germline BRCA wild-type, cisplatin monotherapy was administered based on the increasing evidence of safety and efficacy of platinum for breast cancer. After three cycles of cisplatin treatment, the patient’s metastatic lesions dramatically improved without any major toxicity, and she completed 17 cycles with good response. This case study indicates that patients with heavily pretreated TNBC can potentially achieve a good response to cisplatin monotherapy.
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) [1]; TNBC accounts for 15%–20% of all breast cancers [2]. Generally, it has been well known that TNBC appears at a younger age and has a more aggressive clinical course than other breast cancer subtypes [3]. Although several clinical trials for TNBC have suggested a potential survival benefit using targeted agents, such as poly ADP-ribose polymerase (PARP) inhibitors or immune modulating agents, there are limitations in using these agents in daily practice due to domestic guidelines [4,5]. Thus, cytotoxic chemotherapy still remains the main therapeutic strategy for metastatic TNBC along with palliative radiotherapy and/or surgery [6,7]. However, to date, the treatment response of patients with advanced TNBC has been unsatisfactory [8].
In the presence of germline breast cancer susceptibility gene (BRCA) 1/2 mutations, PARP inhibitors or platinum agents can be considered as palliative regimens after the failure of taxanes, anthracyclines, antimetabolites, and microtubule inhibitors. Platinum is a cytotoxic agent and one of the most widely used drugs for treating solid tumors. Cisplatin, a bifunctional DNA cross-linking agent, induces cell apoptosis by causing DNA damage and interfering with the DNA repair mechanism [9]. The side effects of cisplatin include myelosuppression, nephrotoxicity, neurotoxicity, and nausea/vomiting. However, compared to other regimens, including taxanes and anthracyclines, the side effects of cisplatin are generally mild-to-moderate and manageable. While cisplatin is not usually included in the adjuvant or neoadjuvant chemotherapy for breast cancer, cisplatin-based combination therapy has recently been reported to be highly efficacious in metastatic breast cancer patients with a germline BRCA mutation [10,11]. However, the clinical impact of cisplatin monotherapy as a palliative treatment for BRCA-negative metastatic TNBC patients with a poor general condition has not yet been fully evaluated.
When selecting a therapeutic agent for advanced breast cancer with multiple metastases, it is important to carefully determine a regimen with minimal adverse effects to preserve the patients’ quality of life. Therefore, in this case report, we describe our successful experience of administering cisplatin monotherapy to treat a 51-year-old woman who previously underwent multiple systemic chemotherapies for widespread BRCA-negative TNBC.
A 51-year-old woman was transferred from a nearby hospital after receiving heavy pretreatment for disseminated breast cancer. At the time of admission to our hospital in July 2017, the patient’s general condition was poor, with an Eastern Cooperative Oncology Group (ECOG) performance status of 4. She complained of widespread skin metastases with discharge and generalized edema (Fig. 1). According to her medical history, the patient was diagnosed with inoperable advanced TNBC and underwent 10 cycles of palliative chemotherapy with docetaxel and doxorubicin from May to December 2015, resulting in a partial response. However, the treatment was terminated owing to intolerance of the cumulative doxorubicin dose. Thereafter, the patient underwent a palliative modified radical mastectomy in December 2015. With ongoing disease progression, she received palliative radiotherapy and multiple lines of chemotherapy, including paclitaxel, gemcitabine, capecitabine, vinorelbine, and eribulin, before visiting our hospital.
At the time of admission, the patient’s vital signs were stable and she was alert. Her chest computed tomography (CT) scan demonstrated a diffuse infiltrative mass lesion in the anterior chest wall with bilateral pleural effusion and multiple metastatic lymphadenopathies in both the neck and axilla. The abdomen-pelvis CT scan revealed multiple liver, lymph nodes, and abdominal wall metastases. Tissue biopsy of the right chest wall tumor mass identified the tumor as a triple-negative-type invasive ductal carcinoma (Fig. 2). Cisplatin monotherapy was selected based on the results of several pilot studies, which revealed a remarkable efficacy of cisplatin for TNBC [12,13]. We also took into consideration the patient’s poor general condition and the mild cisplatin-induced toxicity. The patient received 75 mg/m2 of cisplatin every 3 weeks, along with standard hydration and antiemetic prophylaxis. Chemotherapy was administered in an in-patient setting because of the patient’s poor general condition and the extensive dressing care needed for the metastatic skin lesions. After three cycles of cisplatin, the occurrence of skin ulcerative lesions was remarkably decreased. As the patient’s ECOG performance status was dramatically improved to 1, the treatment was continued in an outpatient setting. After six cycles of the regimen, responses were further noted in both the liver and skin lesions (Fig. 3). With regard to adverse events, transient neutropenia and mild nausea were identified, yet both were manageable. The patient recently completed her 17th cycle of cisplatin with a good performance and minimal peripheral neuropathy (Fig. 4).
Although she has no family history of breast or ovarian cancer, germline and somatic BRCA mutation tests were performed in the peripheral blood and primary/residual malignant tumor tissues for the potential use of a PARP inhibitor. However, no pathogenic BRCA mutation was identified (Table 1).
The patient provided written informed consent for publication of clinical details and images.
The National Comprehensive Cancer Network (NCCN) guidelines currently suggest platinum monotherapy as an alternative for metastatic TNBC based on the results of two small single arm phase II clinical trials [7,14,15]. In the TBCRC009 trial, although the tolerable response rate to platinum monotherapy was 25.6% in metastatic TNBC, progression-free survival was only 2.9 months, which was a disappointing result with respect to considering platinum as a first-line treatment [14]. However, this case showed that cisplatin monotherapy can be safe and effective for managing heavily pretreated TNBC patients without any major toxicities; thus, cisplatin monotherapy represents a possible palliative therapeutic option, although the current international guidelines do not recommend its routine use, especially for patients without germline BRCA 1/2 mutations [7].
BRCA1 plays a key role in the homologous recombination (HR) DNA repair system by initiating the repair of DNA double-strand breaks and thereby maintaining DNA stability, which makes it a potential predictive biomarker for DNA-damaging agents, such as platinum [16]. Moreover, a specific TNBC subtype harboring BRCA mutations has been shown to be more sensitive to cisplatin than taxane [17]. Nevertheless, in the current case, whole-genome sequencing of the blood and tumor tissue samples showed no pathogenic somatic or germline BRCA mutation. Interestingly, the germline BRCA mutation status was not found to play any predictive role in carboplatin efficacy in the GeparSixto trial, although carboplatin did generate a higher response rate in the TNBC subgroup [18]. Additionally, a preclinical study reported that, similar to the BRCA1-mutant cell type, a non-BRCA1 mutant basal-like cell line had a considerably high sensitivity to cisplatin treatment. Therefore, such an inconsistency in the efficacy of platinum agents against breast cancer with BRCA mutations suggested that BRCA mutation status might be insufficient for showing HR DNA repair abnormalities.
Instead of identifying the existence of BRCA mutations, “BRCAness” can be an alternative explanation for the existence of HR DNA repair abnormalities. For instance, homologous recombination deficiency (HRD) score, which is a measurement of BRCA promoter methylation, loss of heterozygosity, large-scale state transitions, or telomeric allelic imbalance, using next-generation sequencing can indicate BRCAness. In various small-sized retrospective and post hoc analyses, the HRD score has been highly correlated with the response to platinum-based treatment of TNBC patients with or without BRCA mutations [19]. However, in the TNT trial, no statistically significant difference in the response has been identified according to HRD score; long-term studies for estimating the advantages of platinum for TNBC patients are still warranted [20]. Although the DNA repair mechanism is extremely complex, a comprehensive genomic alteration test should be conducted to understand the actual efficacy of DNA-targeting agents for DNA repair and facilitate the exploration of alternative mechanisms underlying cancer progression and resistance to chemotherapeutic agents.
In this case report, a dramatic and durable response to cisplatin monotherapy was observed in a heavily pretreated TNBC patient with a poor performance status. Although platinum agents have shown effective clinical outcomes for BRCA-mutated TNBC, they should also be considered as an option for treating advanced TNBC without BRCA mutations.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Fig. 1.
Heavily pretreated breast cancer with widespread skin metastases on July 2017. At the time of admission to our hospital, the patient was suffering from severe skin metastases with discharge (A, B). Positron emission tomography-computed tomography shows breast cancer with multiple metastases in the chest wall, liver, bone, and lymph nodes (C). The patient provided written informed consent for publication of clinical details and images.
Fig. 2.
Representative histological features and immunohistochemical (IHC) findings of the metastatic carcinoma. The metastatic tumor shows the histologic grade 3, according to the modified Nottingham grading system (tubule formation 3, nuclear pleomorphism 3, and mitotic activities 2), and frequent lymphovascular emboli (A, arrowheads) within the dermal area (A, B). The tumor cells shows 10% Ki-67 labeling index (C), loss of estrogen receptor (D), and progesterone receptor (E). The expression of HER2 was classified as 2+ (F) on IHC, subsequently proven HER2 negativity on HER2 silver in situ hybridization (not shown) (hematoxylin and eosin stain, ×40 [A, B]; IHC stain, ×200 [C−F]).
Fig. 3.
Before the cisplatin treatment, the patient complained of widespread skin metastases with discharge and generalized edema (A). She received 75 mg/m2 of cisplatin every 3 weeks, along with standard hydration and antiemetic prophylaxis. After three cycles of cisplatin, skin ulcerative lesions were remarkably decreased (B). After six cycles of the regimen, responses were further noted in skin lesions as well as liver, chest wall, and lymph nodes (C). The patient completed her 17th cycle of cisplatin with dramatic metastatic skin lesion improvement (D, E). The patient provided written informed consent for publication of clinical details and images.
Fig. 4.
Computed tomography (CT) shows the impressive response of cisplatin monotherapy. Before the cisplatin monotherapy, multiple metastases with bilateral pleural effusion (arrows) were found in the chest and abdomen CT (July 2017) (A). Pleural effusion and metastatic lesions were dramatically improved (arrowheads) after the cisplatin treatment (December 2018) (B).
Table 1.
Summary of BRCA mutation assay results (no pathogenic mutation was identified)
Germline (blood) Breast tumor at diagnosis Skin lesion prior to cisplatin monotherapy
Nucleotide Amino acid SNP no. Nucleotide Amino acid SNP no. Nucleotide Amino acid SNP no.
BRCA1 c.5383C>T p.Leu1795Phe rs878854958
c.4837A>G p.S1613G rs1799966 c.4837A>G p.Ser1613Gly rs1799966 c.4837A>G p.Ser1613Gly rs1799966
c.4308T>C p.S1436= rs1060915 c.4308T>C p.Ser1436= rs1060915 c.4308T>C p.Ser1436= rs1060915
c.3548A>G p.K1183R rs16942 c.3548A>G p.Lys1183Arg rs16942 c.3548A>G p.Lys1183Arg rs16942
c.3113A>G p.E1038G rs16941 c.3113A>G p.Glu1038Gly rs16941 c.3113A>G p.Glu1038Gly rs16941
c.2612C>T p.P871L rs799917 c.2612C>T p.Pro871Leu rs799917 c.2612C>T p.Pro871Leu rs799917
c.2311T>C p.L771 rs16940 c.2311T>C p.Leu771= rs16940 c.2311T>C p.Leu771= rs16940
c.2082C>T p.S694= rs1799949 c.2082C>T p.Ser694= rs1799949 c.2082C>T p.Ser694= rs1799949
c.441+36_441+38delCTT rs147856441 c.441+36_441+38delCTT rs147856441
c.-19-115T>C rs3765640 c.-19-115T>C rs3765640
BRCA2 c.1114A>C p.N372H rs144848 c.1114A>C p.Asn372His rs144848 c.1114A>C p.Asn372His rs144848
c.3807T>C p.V1269= rs543304 c.3807T>C p.Val1269= rs543304 c.3807T>C p.Val1269= rs543304
c.4563A>G p.Leu1521= rs206075 c.4563A>G p.Leu1521= rs206075
c.6513G>C p.Val2171= rs206076 c.6513G>C p.Val2171= rs206076
c.7393G>A p.Ala2465Thr
c.7397C>T p.Ala2466Val rs169547 c.7397C>T p.Ala2466Val rs169547

SNP, single-nucleotide polymorphism.

  • 1. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010;15(Suppl 5):39–48.ArticlePubMed
  • 2. O’Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, et al. Therapeutic targets in triple negative breast cancer. J Clin Pathol 2013;66:530–42.ArticlePubMed
  • 3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429–34.ArticlePubMed
  • 4. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523–33.ArticlePubMed
  • 5. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379:753–63.ArticlePubMedPMC
  • 6. Mersin H, Yildirim E, Berberoglu U, Gulben K. The prognostic importance of triple negative breast carcinoma. Breast 2008;17:341–6.ArticlePubMed
  • 7. National Comprehensive Cancer Network (NCCN). NCCN guidelines: breast cancer (version 3.2019) [Internet]. Plymouth Meeting (PA): NCCN; 2019 Available at:
  • 8. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164–72.ArticlePubMed
  • 9. Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 2011;3:1351–71.ArticlePubMedPMC
  • 10. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19:1847–52.ArticlePubMedPDF
  • 11. Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010;19:246–8.ArticlePubMed
  • 12. Agrawal LS, Mayer IA. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice? Clin Adv Hematol Oncol 2014;12:654–8.PubMed
  • 13. Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guilhaume MN, Escalup L, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011;22:848–56.ArticlePubMedPDF
  • 14. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015;33:1902–9.ArticlePubMedPMC
  • 15. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145–53.ArticlePubMedPMC
  • 16. Cortesi L, Masini C, Cirilli C, Medici V, Marchi I, Cavazzini G, et al. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer 2010;10:90.ArticlePubMedPMCPDF
  • 17. Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, et al. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010;70:1700–10.ArticlePubMed
  • 18. Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A, et al. Germline mutation status, pathological complete response, and disease-free survival in triple negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol 2017;3:1378–85.ArticlePubMedPMC
  • 19. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016;22:3764–73.ArticlePubMedPMC
  • 20. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med 2018;24:628–37.ArticlePubMedPMCPDF

Figure & Data



    Citations to this article as recorded by  
    • Zeolitic Imidazole Framework/Silica Nanocomposite for Targeted Cancer Therapeutics: Comparative Study of Chemo-Drug Cisplatin (CPt) and Green Platinum (GPt) Efficacy
      Hend Ghnaim Alotaibi, Eman Al-Abbad, Dana Almohazey, Vijaya Ravinayagam, Sultan Akhtar, Hatim Dafalla, B. Rabindran Jermy
      International Journal of Molecular Sciences.2024; 25(6): 3157.     CrossRef
    • Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
      Nityanand Srivastava, Salman Sadullah Usmani, Rajasekaran Subbarayan, Rashmi Saini, Pranav Kumar Pandey
      Frontiers in Oncology.2023;[Epub]     CrossRef
    • Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway
      Lu-Yao Zhang, Zhi-Xin Shen, Lu Guo
      Cancer Investigation.2022; 40(4): 313.     CrossRef
    • Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer
      Reyhaneh Farghadani, Rakesh Naidu
      International Journal of Molecular Sciences.2022; 23(4): 2144.     CrossRef
    • Atorvastatin improves cisplatin sensitivity through modulation of cholesteryl ester homeostasis in breast cancer cells
      Diandra Zipinotti dos Santos, Isabella dos Santos Guimaraes, Mariam F. Hakeem-Sanni, Blake J. Cochran, Kerry-Anne Rye, Thomas Grewal, Andrew J. Hoy, Leticia B. A. Rangel
      Discover Oncology.2022;[Epub]     CrossRef
    • Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
      Andrew Sulaiman, Sarah McGarry, Jason Chambers, Emil Al-Kadi, Alexandra Phan, Li Li, Karan Mediratta, Jim Dimitroulakos, Christina Addison, Xuguang Li, Lisheng Wang
      International Journal of Molecular Sciences.2020; 21(16): 5788.     CrossRef
    • Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review
      Jelena S. Katanic Stankovic, Dragica Selakovic, Vladimir Mihailovic, Gvozden Rosic
      International Journal of Molecular Sciences.2020; 21(20): 7753.     CrossRef


    JYMS : Journal of Yeungnam Medical Science